Atherosclerotic cardiovascular disease is the major killer in industrialized societies. Treatment of this disorder via LDL lowering, particularly with statin drugs, has been partially effective but no panacea. Many patients developing coronary heart disease (CHD) do not have markedly elevated LDL but rather have low HDL levels, alone or accompanied by hypertriglyceridemia. The strong inverse relationship between HDL levels and atherosclerotic cardiovascular disease has been known for more than 25 years (1), but, surprisingly, no effective therapy specifically directed at HDL has yet been developed. This reflects uncertainty about the mechanisms underlying the protective effect of HDL, and also a lack of attainable therapeutic targets. The oldest theory to explain HDL’s protective relationship is the reverse cholesterol transport (RCT) hypothesis, which holds that HDL mediates the movement of cholesterol from peripheral cells, including macrophage-derived foam cells in the arterial wall, back to the liver, where it is excreted into bile (2) (Figure 1).

The RCT theory evolved from an understanding of the role of HDL in transporting cholesterol through the bloodstream to the liver and the finding that HDL and its major apolipoprotein, apoA-I, could remove cholesterol from foam cells (3, 4). A number of other properties of HDL could also be involved in its protective effect. Thus, HDL can suppress expression of cytokine-induced endothelial cell adhesion molecules and block the migration of macrophages into the subendothelial space of blood vessels. HDL protects LDL from oxidation by a variety of mechanisms and may serve as an anticoagulant and antiplatelet agent (see ref. 5). To what extent the various properties of HDL influence the progression of cardiovascular disease remains uncertain.

Evidence for a direct protective effect of HDL in atherosclerosis came with the development of transgenic mice overexpressing the major HDL apoprotein, apoA-I. Transgenic mice expressing human apoA-I have increased HDL levels and are substantially protected from developing atherosclerosis, induced either by diet or genetic manipulation (5). Furthermore, serum from apoA-I transgenic rats stimulates cellular cholesterol efflux to a greater extent than normal serum (6), and apoA-I transgenic mice have increased transport of cholesterol to the liver (7); apoA-I knockout mice, conversely, have decreased flux (8). Placing the apoA-I transgene in the background of the otherwise proatherogenic apoE deletion genotype yields mice that are protected from atherosclerosis, even though they show no alteration of endothelial adhesion molecule (VCAM-1, ICAM-1) expression in lesions or of oxidation-associated epitopes in plasma (9). While not conclusive, these findings are consistent with increased RCT as the protective mechanism in these animals.

**HDL and human atherogenesis**

Evidence relating HDL, RCT, and atherogenesis in humans has been even more difficult to obtain. Human genetic deficiency states affecting HDL levels should offer insight into this question. An appreciable fraction of subjects with low HDL due to rare apoA-I gene mutations have premature atherosclerosis, but many of these subjects do not. Mutations in the plasma cholesteryl ester transfer protein ( CETP), which facilitates the return of HDL cholesterol to the liver via the triglyceride-rich lipoproteins (Figure 1), result in increased HDL levels (10). Heterozygotes with this mutation may have increased CHD risk, consistent with the RCT theory (11). However, homozygous CETP deficiency with very high HDL levels appears to be associated with decreased CHD risk (11), probably reflecting additional protective effects operating at high HDL levels.

Studies in Tangier disease (TD) have shed further light on this complex question. Homozygous TD is a rare disorder associated with extremely low levels of HDL cholesterol (less than 5% of normal) and apoA-I (less than 1%). The hallmark pathology is cholesteryl ester (CE) accumulation in tissue macrophages, leading to accumulation of foam cells in various organs, such as the liver and spleen. Importantly, fibroblasts from Tangier subjects show a dramatic reduction in cholesterol and phospholipid efflux to apoA-I, indicating a defect in the initial step of RCT as the key cellular defect (12).

Moreover, a systematic survey of TD patients suggests that homozygotes have an approximately four- to sixfold increased risk of atherosclerotic cardiovascular disease, compared with age-matched controls (13). While not as striking as the increased risk seen in familial hypercholesterolemia, Tangier homozygotes also have reduced LDL cholesterol (40% of normal), which may partly offset the decrease in RCT. Obligate heterozygotes for the TD mutation have decreased HDL cholesterol (about 50% of normal), normal LDL cholesterol, and an apparent increase in risk for atherosclerosis (13).

**The ABCs of RCT**

Recently, TD was shown to be caused by mutation in an ATP binding cassette transporter, ABCA1 (or ABC1) (14–16). This finding immediately provided a potential explanation for the cellular defect, since ABCA1 stimulates cholesterol and phospholipid efflux to apoA-I and may act as a cholesterol/phospholipid flippase at the plasma membrane (17–19).

In this issue of the *JCI*, Clee et al. (20) provide important further evidence strengthening the link between defec-
Figure 1
HDL-mediated RCT. ABCA1 is involved in transfer of free cholesterol (FC) and phospholipids (PL) from macrophages to apoA-I. Lecithin cholesterol acyltransferase (LCAT) converts FC to CE. CETP and PLTP modify HDL by transferring CE and PL between HDL and triglyceride-rich lipoproteins. HDL delivers cholesterol to liver via SR-BI-mediated selective uptake of the lipids.

A key aspect of this study (20) is the demonstration of a relationship between the defect in cellular cholesterol efflux and HDL levels in subjects with heterozygous ABCA1 mutations. Heterozygotes were found to have wide variation in HDL levels, with the low HDL phenotype becoming more evident at later age. Variations in cholesterol efflux in a fibroblast assay correlated well with HDL levels. Together with the results of an earlier study (22), these findings indicate that variation in ABCA1 function leads to different levels of cellular cholesterol efflux and correlates with HDL levels and HDL size. HDL levels in heterozygotes are comparable to those seen in epidemiological studies, providing plausibility to the theory that differences in efficiency of RCT underlie the relationship between HDL and cardiovascular disease in at least some part of the general population. However, it is likely that low HDL in the general population represents a diversity of different disorders, in some cases reflecting defective RCT, and in other cases reflecting increased remnant levels or defective apoA-I synthesis. The development of molecular markers for the underlying defects should allow more suitable classification of low HDL disorders in the future.

It is perhaps surprising that differences in ABCA1 expression have such a large effect on plasma HDL levels. ABCA1 stimulates cholesterol and phospholipid efflux to free apoA-I, but has only a minor effect on efflux to HDL (17). ABCA1 binds and can be crosslinked to free apoA-I but not HDL. These findings are consistent with earlier studies suggesting that a minor, pre-β HDL fraction (which includes free or minimally lipidated apoA-I) plays a unique role in stimulating the initial phase of cellular cholesterol efflux (23). Strikingly, ABCA1 appears to be saturated at very low concentrations of free apoA-I (less than 15 μg/ml) (17); this compares with a plasma concentration of apoA-I of about 1 mg/ml, of which about 60–120 μg/ml might be in the form of pre-β HDL or free apoA-I. This plasma concentration would be more than adequate to saturate cellular ABCA1, but the concentration of free apoA-I in atherosclerotic lesions, where foam cells reside, is unknown. Nevertheless, a recent report indicates that the concentration of pre-β HDL in human peripheral lymph is about 15 μg/ml (24). Therefore, it seems likely that a very small pool of free apolipoprotein (apoA-I or apoA-IV) acts as the substrate for ABCA1. This free apoA-I may be secreted from the liver or small intestine or may be regenerated in the circulation as a result of remodeling of HDL by CETP, followed by the action of hepatic lipase. Both the concentration of free apoA-I in tissues and the level of ABCA1 expression in cells may be critical for the initial lipolysis of apoA-I. Low levels of ABCA1 expression result in reduced lipolysis and hypercatabolism of apoA-I. A second stage of maturation of HDL involves the actions of lecithin cholesterol acyltransferase (LCAT) and phospholipid transfer protein (PLTP), leading to the formation of mature plasma HDL (25). Large, apoE-rich HDLs appear to be the optimal substrates for scavenger receptor B1 (SR-B1), which plays a major role in extracting CEs from particles in the liver (26, 27).

A striking feature of ABCA1 gene expression is its marked upregulation in foam cells (28), which was recently shown to be mediated by binding of the oxysterol-activated nuclear hormone receptor LXR, in combination with RXR, to a direct repeat four element in the proximal promoter ABCA1.
The Journal of Clinical Investigation | November 2000 | Volume 106 | Number 10


